Autism, also known as autism spectrum disorder (ASD), is a neurodevelopmental condition affecting communication, behavior, and social interaction. According to the World Health Organization, it accounts for around 1 in 100 children worldwide. With a growing demand for better therapies, advancements in autism spectrum disorder therapeutics are gaining momentum. Recent breakthroughs in gene therapy, novel drug formulations, increasing public awareness, and substantial research investments in targeted treatments are driving significant growth in the drug market for ASD. The autism spectrum disorder pipeline analysis by Expert Market Research examines emerging drug candidates, clinical trials, and regulatory progress, highlighting innovative treatments expected to shape the market in the coming years.
Major companies involved in the autism spectrum disorder pipeline analysis include Astrogen, Inc., Vanda Pharmaceuticals, and others.
Leading drugs currently in the pipeline include AST-001, ML-004, and others.
Advancements in gene-editing technologies, increased trials for (N-Methyl-D-Aspartate) NMDA receptor modulators, and rising funding for oxytocin-based therapies are driving growth in the drug pipeline, leading to innovative treatment options.
The Autism Spectrum Disorder Pipeline Analysis Report by Expert Market Research gives comprehensive insights into autism spectrum disorder therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for autism spectrum disorder. The autism spectrum disorder report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The autism spectrum disorder pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with autism spectrum disorder treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to autism spectrum disorder.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by challenges in communication, behavior, and social interaction. It results from a combination of genetic and environmental factors that influence brain development. Individuals with ASD experience a wide range of symptoms, varying in severity.
Autism spectrum disorder treatment focuses on symptom management through behavioral therapy, medications, and support. FDA-approved drugs like Risperidone (Risperdal) and Aripiprazole (Abilify) help manage irritability and aggression in children. These drugs remain crucial in the autism spectrum disorder pipeline, aimed at improving their therapeutic effectiveness and providing better treatment options for ASD symptoms.
According to the World Health Organization, autism spectrum disorder (ASD) affects approximately 1 in 100 children globally. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 estimates 61.8 million individuals with ASD, with an age-standardized prevalence of 788.3 per 100,000 people. The autism spectrum disorder pipeline analysis highlights emerging drug candidates, addressing the increasing need for effective treatments to improve patient outcomes and reduce the global burden of the disorder.
This section of the report covers the analysis of autism spectrum disorder drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 57.32%, covers a major share of the total autism spectrum disorder clinical trials, showcasing significant development potential. Phase 1 follows with 17.07%, demonstrating early-stage progress. Early Phase 1 accounts for 2.44%, reflecting early exploratory studies. Phase 3 represents 17.07%, while Phase 4 comprises 6.10%. These phases collectively drive innovation and promise to significantly impact the ASD market with improved therapeutics.
The drug molecule categories covered under the autism spectrum disorder pipeline analysis include small molecules, monoclonal antibodies, peptides, gene therapies, RNA-based therapies, stem cell therapies, and others. The autism spectrum disorder report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for autism spectrum disorder. In the pipeline, several drug classes are under investigation. For instance, selective serotonin reuptake inhibitors (SSRIs), like escitalopram, are being studied for their potential to improve irritability and behavioral issues in ASD patients.
The EMR report for the autism spectrum disorder pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed autism spectrum disorder therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in autism spectrum disorder clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for autism spectrum disorder. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of autism spectrum disorder drug candidates.
AST-001, developed by Astrogen, Inc., is a novel syrup formulation of L-serine designed to treat core symptoms of autism spectrum disorder (ASD) in pediatric patients. It is a part of a Phase III study, which aims to assess its efficacy and safety compared to a placebo. AST-001 has shown promising results in improving adaptive behavior and social cognition by targeting dopamine neuron activity. The trial, a randomized, double-blind, placebo-controlled study, is expected to conclude by June 2025, with dosage recommendations based on body weight for optimized ASD symptom management.
ML-004 is an investigational small molecule drug targeting the 5-HT1B receptor. It is being evaluated in a Phase 2 open-label extension study for autism spectrum disorder (ASD) by MapLight Therapeutics. The study is designed to assess the safety and tolerability of ML-004, which functions as a serotonin 1B receptor agonist to modulate serotonin signaling, a pathway often implicated in ASD. By targeting serotonin pathways, ML-004 aims to offer potential therapeutic benefits for individuals with ASD, addressing symptoms such as social deficits and repetitive behaviors.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Autism Spectrum Disorder Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for autism spectrum disorder. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within autism spectrum disorder pipeline insights.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share